TAKE Solutions Limited (TAKE) AI Stock Analysis

• Market Cap: ₹5.53B
• Dividend Yield: N/A
• Average Volume (3M): 58.94K
• Price to Earnings (P/E): 131.6
• Beta (1Y): 1.35
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 203
• Sector: Services
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 147,934,000
• 10 Day Avg. Volume: 129,011
• 30 Day Avg. Volume: 58,943
• PEG Ratio: -0.02
• Price to Book (P/B): 5.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: ₹36.00 ▼(-11.15% Downside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is held down primarily by weak financial performance (zero FY2025 revenue, operating losses, and volatile/weak recent cash flow), despite some balance-sheet improvement in FY2025. Technicals are supportive due to a strong uptrend, but overbought signals reduce confidence. Valuation is moderate based on the P/E, with no dividend data to add support.

Positive Factors

Balance-sheet improvement: zero reported debt, positive equity in FY2025

The recovery to positive equity and a reported zero debt position in FY2025 materially improves financial flexibility and reduces interest expense vulnerability. Over a multi-month horizon this gives the company more runway to restructure operations, pursue strategic investments, or withstand revenue recoveries without immediate refinancing risk.

Niche life-sciences software and services focus

A specialized focus on regulated life-sciences software and services creates durable, higher-barrier customer relationships driven by compliance needs. Regulatory stickiness and specialized workflows raise switching costs and support steady long-term demand from pharma/biotech clients if product-market fit and execution normalize.

Prior demonstrated operating cash generation (FY2021–FY2022)

Historical periods of strong operating and free cash flow indicate the business can generate internal funding when revenue and operations align. That prior cash-generation capability suggests operational levers and customer contracts exist which, if reactivated, could support a sustainable recovery without sole reliance on external capital.

Negative Factors

Revenue collapsed to zero in FY2025

Reporting zero annual revenue is a fundamental and durable red flag: it undermines the core business model, eliminates organic funding for operations, and makes customer retention, supplier relationships, and employee retention difficult. Restoring recurring revenue will be a multi-quarter strategic challenge.

Core operations remain unprofitable despite headline net income

Persistent negative operating earnings mean core products and services are not generating sustainable margins; reported net income reflects non-operating items. Long-term viability depends on restoring operating profitability, since reliance on non-recurring or financial gains is not a sustainable earnings model.

Volatile cash flows and prior negative equity raise solvency concerns

Highly inconsistent operating cash flow and a prior swing to negative equity in FY2024 signal recurring solvency risk. Even with FY2025 improvement, such volatility limits strategic flexibility, increases refinancing risk during downturns, and raises the probability that additional capital or restructuring will be required to stabilize operations.

TAKE Solutions Limited Business Overview & Revenue Model

Company Description

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services and solutions in life sciences and supply chain management in the United States, the Asia Pacific, and Europe. The company offers IP-driven and technology backed solutions, consulting, and functional services across clinical, regulatory, and safety for life sciences industry. It also provides clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance/safety services. In addition, the company provides IT infrastructure and support, supply chain management, engineering, designing, and sourcing services. It serves to large and small innovator biopharmaceutical and devices companies, as well as generics manufacturers. The company was incorporated in 2000 and is headquartered in Chennai, India. TAKE Solutions Limited is a subsidiary of TAKE Solutions Pte. Limited.

How the Company Makes Money

null

TAKE Solutions Limited Financial Statement Overview

Summary

Overall financial quality is weak: revenue has contracted to zero in FY2025, operating earnings remain deeply negative despite positive net income (suggesting non-operating influence), and cash flow has been volatile with negative operating cash flow again in FY2025. The balance sheet improved in FY2025 (positive equity and no debt reported), but the prior negative equity in FY2024 is a major stability risk.

Income Statement

Profitability and growth quality are weak and volatile. Revenue has contracted sharply over time, culminating in FY2025 annual revenue reported at zero (following declines from FY2020 through FY2024), which heavily pressures business durability. While FY2025 shows a large positive net income, operating earnings remain deeply negative (EBIT loss), suggesting earnings are not being generated from core operations and may be influenced by non-operating items. Margins also swing materially across years, reinforcing inconsistency in the underlying earnings profile.

Balance Sheet

The balance sheet shows a mixed risk profile. Leverage appears manageable in some years (e.g., moderate debt-to-equity in FY2020–FY2022), but equity turns negative in FY2024, which is a major credit and solvency red flag. FY2025 equity recovers to a positive level and reported total debt is zero, improving headline leverage, but the sharp equity swing year-to-year reduces confidence in balance sheet stability.

Cash Flow

Cash generation is inconsistent. The company produced strong positive operating cash flow and free cash flow in FY2021–FY2022, but free cash flow turned negative in FY2023 and operating cash flow turned negative again in FY2025. FY2024 is positive but modest versus the scale of losses in that year, indicating limited ability to self-fund during weaker periods. Overall, cash flow volatility and recent deterioration weigh on the score despite earlier strengths.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	85.23M	0.00	656.08M	1.89B	6.53B	7.74B
Gross Profit	-250.00K	-450.00K	411.67M	1.06B	4.60B	5.86B
EBITDA	49.91M	27.44M	-1.05B	-209.79M	269.00M	-2.86B
Net Income	481.77M	374.67M	-1.20B	-1.00B	-7.82B	-4.52B
Balance Sheet
Total Assets	352.13M	364.79M	881.05M	2.24B	12.23B	18.45B
Cash, Cash Equivalents and Short-Term Investments	1.50M	156.91M	8.49M	113.36M	290.71M	390.45M
Total Debt	0.00	0.00	370.85M	463.69M	779.90M	5.50B
Total Liabilities	95.84M	159.52M	969.78M	1.16B	10.42B	7.20B
Stockholders Equity	256.29M	205.27M	-88.73M	1.09B	1.81B	11.25B
Cash Flow
Free Cash Flow	-31.39M	-163.66M	14.00M	-123.81M	890.99M	1.32B
Operating Cash Flow	-31.39M	-163.66M	93.16M	200.15M	1.20B	1.35B
Investing Cash Flow	270.00K	220.20M	-74.62M	-21.25M	-306.41M	-569.89M
Financing Cash Flow	-130.00K	-32.39M	-117.35M	-357.21M	-545.17M	-839.46M

TAKE Solutions Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SECMARK	73 Outperform	₹1.13B	-15.68	―	―	28.58%	68.42%
BSL	58 Neutral	₹1.24B	33.72	―	0.51%	-0.22%	-51.08%
DHRUV	56 Neutral	₹579.05M	-0.73	―	0.42%	-9.83%	-5.90%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
TAKE	50 Neutral	₹5.53B	131.64	―	―	―	―